Latest News
-
OXFORD, United Kingdom — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will present data at two upcoming international conferences: the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 16-20, 2023, in Los Angeles, and the International Society for Extracellular Vesicles (ISEV) Annual...
-
BALA CYNWYD, Pa. — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, announced preliminary top-line data from the 25 mg cohort of its Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in participants with Friedreich’s ataxia (FA). Participants in...
-
CAMBRIDGE, Mass. — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alex C. Sapir as chief executive officer and president, effective July 1st, 2023. Upon assuming his new role, Mr. Sapir will also...